Chymostatin

Summary

Chymostatin is a naturally occurring peptide aldehyde originally isolated from Streptomyces species. It is a potent, reversible inhibitor of chymotrypsin-like serine proteases and cysteine proteases such as cathepsin B. It is widely used as a research tool in biochemistry and cell biology to inhibit proteolytic degradation in cell lysates and to study protease-dependent pathways. It has no approved clinical indications.

Mechanism of Action

Competitive inhibitor of chymotrypsin-like serine proteases (chymotrypsin, chymase, cathepsin G, and related enzymes); the C-terminal aldehyde group forms a reversible covalent hemiacetal adduct with the active-site serine residue, blocking substrate access and proteolytic activity.

Routes of Administration

Goals & Uses

• Protease inhibitor in cell lysis buffersResearch ToolHigh
• Inhibition of cathepsin G and chymaseResearch / BiochemistryModerate
• Study of apoptosis and autophagy pathwaysResearch / Cell BiologyModerate
• Inhibition of chymotrypsin-like serine proteasesResearch / BiochemistryHigh
• Inhibition of cysteine proteases (cathepsin B)Research / BiochemistryModerate

Contraindications

• Human or animal therapeutic administrationClinical UseHigh

Adverse Effects

• Cytotoxicity at high concentrationsIn Vitro ToxicityUncommon
• Non-specific protease inhibitionOff Target EffectCommon

Drug Interactions

No drug interactions recorded yet.

Population Constraints

• Not for human useGeneral PopulationAbsolute

Regulatory Status

• European UnionUnapprovedResearch reagent only
• United StatesUnapprovedResearch reagent only; sold under laboratory-use exemptions, not as a drug
• United KingdomUnapprovedResearch reagent only

Chymostatin is not approved for human therapeutic use in any jurisdiction. It is commercially available exclusively as a research reagent (laboratory grade). It is not regulated as a drug or controlled substance.

Evidence & Sources

No sources recorded yet.